| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.04 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.04 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.04 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.065 | 0.04 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.068 | 0.05 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.068 | 0.05 |